Details for New Drug Application (NDA): 207078
✉ Email this page to a colleague
The generic ingredient in LOKELMA is sodium zirconium cyclosilicate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium zirconium cyclosilicate profile page.
Summary for 207078
Tradename: | LOKELMA |
Applicant: | Astrazeneca |
Ingredient: | sodium zirconium cyclosilicate |
Patents: | 14 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 207078
Generic Entry Date for 207078*:
Constraining patent/regulatory exclusivity:
Dosage:
FOR SUSPENSION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 207078
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078 | NDA | AstraZeneca Pharmaceuticals LP | 0310-1105 | 0310-1105-30 | 30 PACKET in 1 BOX (0310-1105-30) / 5 g in 1 PACKET (0310-1105-01) |
LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078 | NDA | AstraZeneca Pharmaceuticals LP | 0310-1105 | 0310-1105-39 | 11 PACKET in 1 BOX (0310-1105-39) / 5 g in 1 PACKET (0310-1105-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 5GM/PACKET | ||||
Approval Date: | May 18, 2018 | TE: | RLD: | Yes | |||||
Patent: | 10,300,087 | Patent Expiration: | Oct 14, 2035 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patented Use: | TREATMENT OF HYPERKALEMIA IN ADULTS | ||||||||
Patent: | 10,335,432 | Patent Expiration: | Feb 10, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF HYPERKALEMIA IN ADULTS | ||||||||
Patent: | 10,398,730 | Patent Expiration: | Feb 10, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF HYPERKALEMIA IN ADULTS |
Expired US Patents for NDA 207078
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-001 | May 18, 2018 | 6,332,985 | ⤷ Subscribe |
Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-002 | May 18, 2018 | 6,332,985 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription